BioMedNewsBreaks – Healthy Extracts Inc.’s (HYEX) HERHEART(TM) Packs a ‘Whole Host of Health Benefits’

Healthy Extracts (OTCQB: HYEX), through its wholly owned subsidiary BergaMet NA(TM), has developed HERHEART(TM), an exclusive supplement scientifically formulated specifically for women to improve perimenopausal symptoms and cardiovascular health. The supplement’s development was influenced by the statistic that cardiovascular disease is the leading cause of death in women globally. A recent article notes, “A 2020 clinical study revealed that HERHEART reduced mood swings and hot flashes by 40% and 60%, respectively, increased energy by 45%, and improved arousal, comfort and desire by between 40% and 70%. It also reduced cholesterol levels, acted as an anti-inflammatory agent and metabolized fat. Dr. Nesochi Okeke-Igbokwe MD. M.S., a trusted and respected international health expert who recently joined HYEX’s Medical Advisory Board, recommends HERHEART to women. ‘This is a supplement that is terrific for women of all ages and has a whole host of health benefits.’”

To view the full article, visit https://ibn.fm/emLPn

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based, and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.

Company subsidiaries BergaMet NA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergaMet NA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus, and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents — two issued and four pending.

For more information, visit: www.HealthyExtractsinc.com, www.BergametNA.com, or www.Fuel4Thought.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Two Years of Clinical Milestones Across Oncology and Rare Disease Programs 

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, announced…

2 days ago

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Expands IP Portfolio with New U.S. Patent Filings

HealthLynked (OTCQB: HLYK), a leader in patient-centric healthcare technology, announced the submission of two new…

2 days ago

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in MarketScreener Editorial on Targeted AI Applications

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for…

3 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted…

4 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy and targeted treatments for…

4 days ago

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast 

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary…

4 days ago